Payment overview · 2025
General Payments
$1,029.85
67 reported records · 13 companies
Healthcare provider profile · identity verified
Jason A Barton, DO
Allopathic & Osteopathic Physicians|Family Medicine · PARKERSBURG, WV · NPI 1407859218
Verified facts
What the public records show
CMS Open Payments records show Jason A Barton, DO received $1,029.85 in general payments during 2025 across 67 reported records.
ABBVIE INC. accounted for 33.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Jardiance, Kerendia, Linzess, Ozempic, Synthroid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 233 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 193 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $347.37 | 33.7% | 28 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $187.75 | 18.2% | 12 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $120.70 | 11.7% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $96.49 | 9.4% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $50.55 | 4.9% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $40.88 | 4.0% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $39.13 | 3.8% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $31.49 | 3.1% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $30.50 | 3.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $27.88 | 2.7% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $21.15 | 2.0% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.17 | 1.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.79 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,029.85 | 67 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $187.75 | 12 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $184.51 | 13 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $140.90 | 10 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $123.83 | 13 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $120.70 | 6 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $74.17 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $61.67 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $60.85 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $50.55 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $40.88 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $39.13 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $39.03 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $39.03 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $34.82 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $31.49 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $30.50 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $27.88 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $21.15 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $19.17 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $16.79 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.89 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $10.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 193 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 233 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 68 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 78 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 72 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
78 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
95 | 21 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
70 | 17 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
233 | 46 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
72 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
68 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
193 | 38 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Pantoprazole Sodium | Pantoprazole Sodium | 902 | 220 |
| Levothyroxine Sodium | Levothyroxine Sodium | 887 | 174 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 621 | 143 |
| Amlodipine Besylate | Amlodipine Besylate | 606 | 153 |
| Atorvastatin Calcium | Atorvastatin Calcium | 583 | 154 |
| Pravastatin Sodium | Pravastatin Sodium | 478 | 121 |
| Alprazolam | Alprazolam | 460 | 71 |
| Losartan Potassium | Losartan Potassium | 445 | 114 |
| Sertraline Hcl | Sertraline Hcl | 430 | 102 |
| Metoprolol Succinate | Metoprolol Succinate | 371 | 101 |
| Trazodone Hcl | Trazodone Hcl | 367 | 93 |
| Montelukast Sodium | Montelukast Sodium | 353 | 82 |
| Gabapentin | Gabapentin | 330 | 72 |
| Omeprazole | Omeprazole | 322 | 79 |
| Metformin Hcl Er | Metformin Hcl | 305 | 74 |
| Furosemide | Furosemide | 282 | 74 |
| Duloxetine Hcl | Duloxetine Hcl | 280 | 51 |
| Lisinopril | Lisinopril | 270 | 76 |
| Tamsulosin Hcl | Tamsulosin Hcl | 258 | 69 |
| Pioglitazone Hcl | Pioglitazone Hcl | 251 | 56 |
| Clopidogrel | Clopidogrel Bisulfate | 249 | 57 |
| Potassium Chloride | Potassium Chloride | 244 | 50 |
| Jardiance | Empagliflozin | 233 | 46 |
| Clonazepam | Clonazepam | 200 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 198 | 54 |
| Allopurinol | Allopurinol | 194 | 45 |
| Fluticasone Propionate | Fluticasone Propionate | 194 | 62 |
| Tramadol Hcl | Tramadol Hcl | 194 | 30 |
| Eliquis | Apixaban | 193 | 38 |
| Valsartan | Valsartan | 192 | 47 |
| Carvedilol | Carvedilol | 184 | 50 |
| Buspirone Hcl | Buspirone Hcl | 174 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 170 | 49 |
| Glimepiride | Glimepiride | 165 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 164 | 49 |
| Fenofibrate | Fenofibrate | 141 | 30 |
| Atenolol | Atenolol | 136 | 40 |
| Ezetimibe | Ezetimibe | 133 | 31 |
| Meloxicam | Meloxicam | 132 | 34 |
| Alendronate Sodium | Alendronate Sodium | 130 | 29 |
| Hydralazine Hcl | Hydralazine Hcl | 130 | 34 |
| Temazepam | Temazepam | 128 | 18 |
| Donepezil Hcl | Donepezil Hcl | 126 | 25 |
| Bupropion Xl | Bupropion Hcl | 124 | 28 |
| Lamotrigine | Lamotrigine | 124 | 21 |
| Metformin Hcl | Metformin Hcl | 122 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 118 | 26 |
| Diazepam | Diazepam | 117 | 20 |
| Famotidine | Famotidine | 117 | 36 |
| Methocarbamol | Methocarbamol | 112 | 30 |
| Mounjaro | Tirzepatide | 101 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 99 | 21 |
| Lorazepam | Lorazepam | 99 | 21 |
| Farxiga | Dapagliflozin Propanediol | 95 | 21 |
| Celecoxib | Celecoxib | 94 | 20 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 93 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 92 | 18 |
| Cefdinir | Cefdinir | 91 | 74 |
| Citalopram Hbr | Citalopram Hydrobromide | 91 | 24 |
| Prednisone | Prednisone | 87 | 40 |
| Memantine Hcl | Memantine Hcl | 85 | 16 |
| Simvastatin | Simvastatin | 83 | 21 |
| Pregabalin | Pregabalin | 82 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 78 | 21 |
| Synthroid | Levothyroxine Sodium | 78 | 19 |
| Aripiprazole | Aripiprazole | 76 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 76 | 22 |
| Vascepa | Icosapent Ethyl | 75 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 72 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 71 | 21 |
| Symbicort | Budesonide/Formoterol Fumarate | 70 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 70 | 21 |
| Ozempic | Semaglutide | 68 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 65 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 64 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 62 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 62 | 28 |
| Diclofenac Sodium | Diclofenac Sodium | 59 | 15 |
| Warfarin Sodium | Warfarin Sodium | 59 | suppressed |
| Finasteride | Finasteride | 58 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 57 | 48 |
| Ropinirole Hcl | Ropinirole Hcl | 57 | 13 |
| Clonidine Hcl | Clonidine Hcl | 56 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 56 | 18 |
| Azelastine Hcl | Azelastine Hcl | 55 | 24 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 55 | 14 |
| Trulicity | Dulaglutide | 55 | 11 |
| Ondansetron Odt | Ondansetron | 54 | 27 |
| Amoxicillin | Amoxicillin | 53 | 44 |
| Enalapril Maleate | Enalapril Maleate | 52 | 16 |
| Baclofen | Baclofen | 51 | 14 |
| Bumetanide | Bumetanide | 51 | 16 |
| Mirtazapine | Mirtazapine | 50 | 15 |
| Tradjenta | Linagliptin | 50 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 48 | 13 |
| Nifedipine Er | Nifedipine | 48 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 47 | 39 |
| Myrbetriq | Mirabegron | 47 | 11 |
| Nystatin | Nystatin | 47 | 25 |
| Spironolactone | Spironolactone | 45 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 44 | 11 |
| Linzess | Linaclotide | 44 | suppressed |
| Xarelto | Rivaroxaban | 43 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 42 | 21 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 42 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 42 | 11 |
| Azithromycin | Azithromycin | 41 | 35 |
| Colestipol Hcl | Colestipol Hcl | 41 | 17 |
| Propranolol Hcl | Propranolol Hcl | 40 | 11 |
| Ramipril | Ramipril | 40 | 12 |
| Fluconazole | Fluconazole | 38 | 25 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 38 | 27 |
| Breo Ellipta | Fluticasone/Vilanterol | 37 | 11 |
| Levetiracetam | Levetiracetam | 36 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 35 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 35 | suppressed |
| Rybelsus | Semaglutide | 35 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | suppressed |
| Methylprednisolone | Methylprednisolone | 34 | 29 |
| Terazosin Hcl | Terazosin Hcl | 32 | 11 |
| Entresto | Sacubitril/Valsartan | 31 | suppressed |
| Repatha Sureclick | Evolocumab | 31 | suppressed |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Primidone | Primidone | 30 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 30 | 15 |
| Solifenacin Succinate | Solifenacin Succinate | 29 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Creon | Lipase/Protease/Amylase | 28 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 28 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 27 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 27 | suppressed |
| Novolog Flexpen | Insulin Aspart | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Nitroglycerin | Nitroglycerin | 26 | 18 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 25 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 25 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Belsomra | Suvorexant | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Cephalexin | Cephalexin | 20 | 16 |
| Clotrimazole | Clotrimazole | 20 | 11 |
| Dexamethasone | Dexamethasone | 20 | 16 |
| Ipratropium Bromide | Ipratropium Bromide | 20 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Ampicillin Trihydrate | Ampicillin Trihydrate | 19 | 15 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 18 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | suppressed |
| Ibu | Ibuprofen | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 12 |
| Fenofibrate | Fenofibrate,micronized | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Entacapone | Entacapone | 12 | suppressed |
| Kerendia | Finerenone | 12 | suppressed |
| Nicardipine Hcl | Nicardipine Hcl | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Roflumilast | Roflumilast | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Indomethacin Er | Indomethacin | 11 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,029.85 · 67 records | ABBVIE INC. | BREZTRI, CREON, ELIQUIS, GEMTESA, JARDIANCE, Kerendia, Korlym, LINZESS, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, SYNTHROID, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error